Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-28T09:30:22.290Z Has data issue: false hasContentIssue false
  • English
  • Français

Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow

Published online by Cambridge University Press:  16 April 2020

B. Spivak ,
D.I. Maline ,
V.N. Kozyrev ,
R. Mester ,
S.A. Neduva ,
R.S. Ravilov  and
A. Weizman
B. Spivak
Affiliation:
Research Unit, Ness Ziona Mental Health Center, POB 1,Ness Ziona74100, Israel Sackler Faculty of Medicine, Tel Aviv University,Tel Aviv, Israel
D.I. Maline
Affiliation:
Moscow Research Institute of Psychiatry, Department of Intensive Therapy, Moscow Psychiatric Hospital No.4, Moscow, Russia
V.N. Kozyrev
Affiliation:
Moscow Psychiatric Hospital No.1,Moscow, Russia
R. Mester
Affiliation:
Research Unit, Ness Ziona Mental Health Center, POB 1,Ness Ziona74100, Israel Sackler Faculty of Medicine, Tel Aviv University,Tel Aviv, Israel
S.A. Neduva
Affiliation:
Moscow Research Institute of Psychiatry, Department of Intensive Therapy, Moscow Psychiatric Hospital No.4, Moscow, Russia
R.S. Ravilov
Affiliation:
Moscow Psychiatric Hospital No.1,Moscow, Russia
A. Weizman
Affiliation:
Sackler Faculty of Medicine, Tel Aviv University,Tel Aviv, Israel Research Unit, Geha Psychiatric Hospital and Laboratory of Biological Psychiatry, Felsenstein Medical Research Center,Petah Tiqva, Israel
Get access

Summary

A ten-year prospective survey of neuroleptic malignant syndrome (NMS) was performed in a major psychiatric hospital (1,510 beds) in Moscow. All inpatients who developed a persistent and severe extrapyramidal rigidity accompanied by fever after exposure to neuroleptic medication were screened for NMS. The diagnosis of NMS was established according to Levenson’s criteria and at a later stage all NMS cases were reevaluated using the DSM-IV research criteria. Data on age, gender and psychiatric diagnoses were analyzed. Of the 78,708 inpatients treated with neuroleptic agents, 19 separate patients had an episode of NMS, for a frequency of 0.02%. Mortality rate was 10.5% (2/19 patients). Of the three potential risk factors studied, only young age (≤ 25 years) was significantly associated with an increased frequency of NMS (P < 0.01). The low rate of NMS found here compared to studies in other countries may be due to the stringent demands for NMS diagnosis. More large-scale prospective studies including detailed clinical and laboratory data are needed to clarify these differences and their impact on the prevalence and risk factors of NMS.

Keywords

frequencymortality rateneuroleptic malignant syndromepossible risk
Type
Original Article
Information
European Psychiatry , Volume 15 , Issue 5 , August 2000 , pp. 330 - 333
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adonizio, GSusman, V.LRoth, S.DSymptoms of neuroleptic malignant syndrome in 82 consecutive inpatients Am J Psychiatry 43 1986 1587–1590Google Scholar
American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994 Washington DC: APAGoogle Scholar
Deng, M.ZChen, G.QPhillips, M.RNeuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study. Am J Psychiatry 147 1990 1149–1155Google ScholarPubMed
Gelenberg, A.JBellinghausen, BWojcil, J.DFalk, W.ESachs, G.SA prospective study of neuroleptic malignant syndrome in a short-term psychiatric hospital Am J Psychiatry 145 1988 517–518Google Scholar
Hermesh, HAizenberg, DWeizman, ALapidot, MMayor, KMunitz, HRisk for definite neuroleptic malignant syndrome: a prospective study in 223 consecutive inpatients Br J Psychiatry 161 1992 254–257CrossRefGoogle Scholar
Keck, P.EJr, Pope HG Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study Am J Psychiatry 144 1987 1344–1346Google Scholar
Keck, P.EJr, Pope HG, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population Am J Psychiatry 148 1991 880–882Google Scholar
Keck, P.EJr, McElroy SL, Pope HG Jr. Neuroleptic malignant syndrome Curr Opinion Psychiatry 4 1991 34–37CrossRefGoogle Scholar
Levenson, J.LNeuroleptic malignant syndrome Am J Psychiatry 142 1985 1137–1145Google ScholarPubMed
Neppe, V.MThe neuroleptic malignant syndrome S Afr Med J 65 1984 523–525Google ScholarPubMed
Rivera, J.MGarcia-Bragado, FIriarte, L.MLozno-Gutierrez, FSalgado, VAndreu, J et al. Neuroleptic malignant syndrome: analysis of 9 cases Med Clin (Barc) 94 1990 121–125Google ScholarPubMed
Sewell, D.DJeste, D.VDistinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illness: a study of 34 cases J Neuropsychiatr Clin Neurosci 4 1992 265–269Google Scholar
Simpson, GAngus, J.W.SA rating scale for extrapyramidal side effects Acta Psychiatry Scand 45 Suppl 212 1970 11–19CrossRefGoogle Scholar
Yegorov, V.FAnd how is it over there, across the ocean? Schizophr Bull 18 1992 1–7CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.